Omega Therapeutics, Inc.
OMGAHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|
| Revenue | $3.1M | $2.1M | $144,000 | — |
| Operating income | −$100.3M | −$102.8M | −$66.0M | −$28.6M |
| Net income | −$97.4M | −$102.7M | −$68.3M | −$29.4M |
| Total assets | $204.4M | $146.0M | $233.3M | $28.1M |
| Total liabilities | $146.3M | $40.0M | $32.7M | $17.5M |
| Equity | $58.0M | $106.0M | $200.6M | −$64.6M |
| EPS (diluted) | $-1.80 | $-2.14 | $-3.05 | — |
| Shares out. | 48.1M | 47.8M | 47.8M | 4.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −3240.5%
- Net margin
- −3148.9%
- Return on equity
- −167.9%
- Return on assets
- −47.7%
- Return on capital (ROCE)
- −56.5%
- Liabilities / assets
- 71.6%
- Debt / equity
- 2.52×
- Book value / share
- $1.21
- Revenue growth (YoY)
- 49.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -6.19distress
- Accruals / assets
- −2.9%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Fmr LlcPassive (13G)Mar 7, 2025
- Flagship V Venturelabs Rx Fund, L.P.Activist (13D)Feb 5, 2025
- Flagship Ventures Fund V, L.P.Activist (13D)Dec 31, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Delisting / listing-standard noticeFeb 24, 2025
- Entered a material agreement · Bankruptcy or receivership · New financial obligationFeb 14, 2025
- Entered a material agreement · Terminated a material agreement · New financial obligation · Delisting / listing-standard notice · Director / officer change · Other material eventFeb 3, 2025
- Director / officer changeJan 28, 2025
- Debt acceleration / triggering eventJan 17, 2025
- Director / officer changeJan 10, 2025
- Director / officer change · Other material eventDec 31, 2024
- Director / officer changeDec 6, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.